TOUCH

Please fill your contact details below:

BE IN

© 2019 by OPTCEUTICS.

SCIENCE

TEAM

SAHAR AWWAD

Sahar’s research background includes the delivery and development of biologics and small molecular weight drugs with particular knowledge in the overcoming the challenges in ocular drug delivery, in particular the vitreous and posterior segment of the eye. Sahar received her PhD in UCL, School of Pharmacy and UCL, Institute of Ophthalmology; and is currently a Research Associate in UCL.

CSO & Co - Founder

STEVE BROCCHINI

Steve is a chemist (BA, Reed College 1984; PhD, University of Michigan, 1989) and is current Professor in Chemical Pharmaceutics. He has been at the UCL School of Pharmacy in London since 1997.  Steve is also a member of the Biomedical Research Centre in Ophthalmology at the UCL Institute of Ophthalmology.  

Scientific Board Member & Co-founder

PENG TEE KHAW

Sir Peng’s research interests are in developing new therapies, particularly for preventing scarring and regeneration, with a special interest in paediatric and young adult glaucoma. He has developed surgical techniques including the Moorfields Safer Surgery System, which have markedly improved the safety and outcomes of antimetabolite-assisted trabeculectomy in many parts of the world. He has also developed anti-scarring regimens, which have led to international clinical trials, and are now in routine use.

Co - founder

YANN BOUREMEL

Yann is a biomedical engineer with strong interest in applied engineering to solve biomedical problems. He has experience in designing long term intraocular medical implants and in developing models to study physiological processes.  He also has an extensive background in microfluidics, bench testing, instrument control, image visualisation techniques, data processing, modelling and rapid prototyping.

Fluid Engineer Consultant

NKIRUKA IBEANU

Nkiru has clinical practice experience following her graduation with a bachelor’s degree in pharmacy in Nigeria. Her expertise in pharmaceutical research stems from both her undergraduate and master’s degree programs in Pharmaceutics at the UCL School of Pharmacy, during which she worked on the formulation and stabilisation of amorphous pharmaceuticals.

Formulation Consultant

SCIENCE

TEAM

SAHAR AWWAD

Sahar’s research background includes the delivery and development of biologics and small molecular weight drugs with particular knowledge in the overcoming the challenges in ocular drug delivery, in particular the vitreous and posterior segment of the eye. Sahar received her PhD in UCL, School of Pharmacy and UCL, Institute of Ophthalmology; and is currently a Research Associate in UCL.

CSO & Co-founder

STEVE BROCCHINI

Steve is a chemist (BA, Reed College 1984; PhD, University of Michigan, 1989) and is current Professor in Chemical Pharmaceutics. He has been at the UCL School of Pharmacy in London since 1997.  Steve is also a member of the Biomedical Research Centre in Ophthalmology at the UCL Institute of Ophthalmology.  

Scientific Board Member, Director & Co-founder

PENG TEE KHAW

Sir Peng’s research interests are in developing new therapies, particularly for preventing scarring and regeneration, with a special interest in paediatric and young adult glaucoma. He has developed surgical techniques including the Moorfields Safer Surgery System, which have markedly improved the safety and outcomes of antimetabolite-assisted trabeculectomy in many parts of the world. He has also developed anti-scarring regimens, which have led to international clinical trials, and are now in routine use.

Co - founder

YANN BOUREMEL

Yann is a biomedical engineer with strong interest in applied engineering to solve biomedical problems. He has experience in designing long term intraocular medical implants and in developing models to study physiological processes.  He also has an extensive background in microfluidics, bench testing, instrument control, image visualisation techniques, data processing, modelling and rapid prototyping.

Fluid Biomedical Engineer Consultant

NKIRUKA IBEANU

Nkiru has clinical practice experience following her graduation with a bachelor’s degree in pharmacy in Nigeria. Her expertise in pharmaceutical research stems from both her undergraduate and master’s degree programs in Pharmaceutics at the UCL School of Pharmacy, during which she worked on the formulation and stabilisation of amorphous pharmaceuticals.

Formulation Consultant

STAVROS VLATAKIS

Stavros earned his MSc in Pharmaceutical Formulation and Entrepreneurship at UCL, School of Pharmacy. His research focused on chemical conjugation and purification of biologics; and on the promotion of breakthrough technologies into the market.

Formulation Consultant

Commercial

TEAM

CHRIS REDHEAD

A seasoned life science professional, Chris brings  a wealth of experience in biopharma ventures.  Following an early career as a cell biologist, Chris spent more than twelve years providing ranked life science equity research and was a founder partner of the investment banking boutique Code Securities latterly Nomura Code. In the decade since founding Aruwon, Chris has helped a host of life science SMEs manage all aspects of corporate and business development including fund raising and M&A.  As a founder of the ocular spin-out Optosolve, Chris secured the funding for development and trans-national out-licensing of its unique topical ophthalmic analgesic; patent protected in major territories and now advancing through clinical development.

CEO, Director & Co-founder

BARRY BUTLER

Barry is an experienced leader with over 30 years of pharmaceutical experience. He held numerous management and executive positions at Glaxo, Inc. and Bausch & Lomb from 1988 until 2001.  In 2001, Barry co-founded Acsentient, Inc., which was sold to Ista in 2002, resulting in the launch of Xibrom® and Istalol®. In 2004, Barry founded Sirion Therapeutics, Inc. a successful ophthalmic pharmaceutical company that developed and launched Durezol® and Zirgan®.

Director & Co-founder

RONIL PATEL

Ronil Patel has over 12 years experience in drug discovery and development. Currently, Ronil is a partner at BLP Management Group, and is responsible for business development and project management. He has extensive operational knowledge of drug development lifecycle development and management. As a project leader on several drug development projects, Ronil created, monitored and maintained timelines for client’s strategic drug development program, as well as coordinated and managed cross-functional teams that involved internal and external (vendors and sponsors) personnel to achieve project goals and meet critical timelines.

Project management & Client Services